Big pharma can ’t get enough of one class of cancer drugs

A world, dealmaking is in a rut. A combination of higher interest rates, geopolitical tensions and economic uncertainty has put a hold on joint ventures, mergers and acquisitions. One exception is targets with in their name. Another, less obvious one, involves a less catchy initialism: s. Makers…#seagen #nurixtherapeutics #amgen #astrazeneca #merck #daiichisankyo #bristolmyerssquibb #susangalbraith #trodelvy #gileadsciences
Source: Reuters: Health - Category: Consumer Health News Source Type: news